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Proliferating mammalian cells use glutamine as a
source of nitrogen and as a key anaplerotic source
to provide metabolites to the tricarboxylic acid cycle
(TCA) for biosynthesis. Recently, mammalian target
of rapamycin complex 1 (mTORC1) activation has
been correlated with increased nutrient uptake and
metabolism, but nomolecular connection to glutami-
nolysis has been reported. Here, we show that
mTORC1 promotes glutamine anaplerosis by acti-
vating glutamate dehydrogenase (GDH). This regula-
tion requires transcriptional repression of SIRT4, the
mitochondrial-localized sirtuin that inhibits GDH.
Mechanistically, mTORC1 represses SIRT4 by pro-
moting the proteasome-mediated destabilization of
cAMP-responsive element binding 2 (CREB2).
Thus, a relationship between mTORC1, SIRT4, and
cancer is suggested by our findings. Indeed, SIRT4
expression is reduced in human cancer, and its
overexpression reduces cell proliferation, transfor-
mation, and tumor development. Finally, our data
indicate that targeting nutrient metabolism in en-
ergy-addicted cancers with high mTORC1 signaling
may be an effective therapeutic approach.INTRODUCTION
Nutrient availability plays a pivotal role in the decision of a cell to
commit to cell proliferation. In conditions of sufficient nutrient
sources and growth factors (GFs), the cell generates enough
energy and acquires or synthesizes essential building blocks at
a sufficient rate to meet the demands of proliferation.840 Cell 153, 840–854, May 9, 2013 ª2013 Elsevier Inc.Conversely, when nutrients are scarce, the cell responds by
halting the biosynthetic machinery and by stimulating catabolic
processes such as fatty-acid oxidation and autophagy to pro-
vide energy maintenance (Vander Heiden et al., 2009). Essential
to the decision process between anabolism and catabolism is
the highly conserved, atypical serine/threonine kinase mamma-
lian target of rapamycin complex 1 (mTORC1), whose activity is
deregulated in many cancers (Menon and Manning, 2008). This
complex, which consists of mTOR, Raptor, and mLST8, is acti-
vated by amino acids (aa), GFs (insulin/IGF-1), and cellular
energy to drive nutrient uptake and subsequently proliferation
(Yecies and Manning, 2011). The molecular details of these
nutrient-sensing processes are not yet fully elucidated, but it
has been shown that aa activate the Rag guanosine-5’-triphos-
phate (GTP)ases to regulate mTORC1 localization to the lyso-
somes (Kim et al., 2008; Sancak et al., 2008), and GFs signal
through the PI3K-Akt or the extracellular signal-regulated kinase
(ERK)-ribosomal protein S6 kinase (RSK) pathways to activate
mTORC1 by releasing the Ras homolog enriched in brain
(RHEB) GTPase from repression by the tumor suppressors
tuberous sclerosis 1 (TSC1)–TSC2 (Inoki et al., 2002; Manning
et al., 2002; Roux et al., 2004). Finally, low-energy conditions
inhibit mTORC1 by activating AMPK and by repressing the
assembly of the TTT-RUVBL1/2 complex (Inoki et al., 2003;
Gwinn et al., 2008; Kim et al., 2013).
Glutamine, the most abundant aa in the body, plays an impor-
tant role in cellular proliferation. It is catabolized to a-ketogluta-
rate (aKG), an intermediate of the tricarboxylic acid (TCA) cycle,
through two deamination reactions in a process termed gluta-
mine anaplerosis (DeBerardinis et al., 2008). The first reaction
requires glutaminase (GLS) to generate glutamate, and the sec-
ond occurs by the action of either glutamate dehydrogenase
(GDH) or transaminases. Incorporation of aKG into the TCA cycle
is the major anaplerotic step critical for the production of
biomass building blocks including nucleotides, lipids, and aa
(Wise and Thompson, 2010). Recent studies have demonstrated
that glutamine is also an important signaling molecule. Accord-
ingly, it positively regulates the mTORC1 pathway by facilitating
the uptake of leucine (Nicklin et al., 2009) and by promoting
mTORC1 assembly and lysosomal localization (Dura´n et al.,
2012; Kim et al., 2013).
Commonly occurring oncogenic signals directly stimulate
nutrient metabolism, resulting in nutrient addiction. Oncogenic
levels of Myc have been linked to increased glutamine uptake
and metabolism through a coordinated transcriptional program
(Wise et al., 2008; Gao et al., 2009). Hence, it is not surprising
that cancer cells are addicted to glutamine (Wise and Thompson,
2010). Thus, considering the prevalence of mTORC1 activation
in cancer and the requirement of nutrients for cell proliferation,
understanding how mTORC1 activation regulates nutrient levels
and metabolism is critical. Activation of the mTORC1 pathway
promotes the utilization of glucose, another nutrient absolutely
required for cell growth. However, no study has yet investigated
if and how the mTORC1 pathway regulates glutamine uptake
and metabolism. Here, we describe a role of the mTORC1
pathway in the stimulation of glutamine anaplerosis by promot-
ing the activity of GDH. Mechanistically, mTORC1 represses
the transcription of SIRT4, an inhibitor of GDH. SIRT4 is a mito-
chondrial-localized member of the sirtuin family of nicotinamide
adenine dinucleotide (NAD)-dependent enzymes known to play
key roles in metabolism, stress response, and longevity (Haigis
and Guarente, 2006). We demonstrate that the mTORC1
pathway negatively controls SIRT4 by promoting the protea-
some-mediated degradation of cAMP-responsive element-
binding (CREB) 2. We reveal that SIRT4 levels are decreased in
a variety of cancers, and when expressed, SIRT4 delays tumor
development in a Tsc2/ mouse embryonic fibroblast (MEF)
xenograft model. Thus, our findings provide insights into how
mTORC1 regulates glutamine anaplerosis, contributing there-
fore to themetabolic reprogramming of cancer cells, an essential
hallmark to support their excessive need for proliferation.
RESULTS
ThemTORC1PathwayRegulatesGlutamineMetabolism
via GDH
The activation of the mTORC1 pathway has recently been linked
to glutamine addiction of cancer cells (Choo et al., 2010), yet it
remains to be resolved whether mTORC1 serves as a regulator
of glutamine anaplerosis. To investigate this possibility, we first
determined the effect of mTORC1 activity on glutamine uptake.
We measured glutamine uptake rates in Tsc2 wild-type (WT)
and Tsc2/ MEFs. We found that Tsc2/ MEFs consumed
significantly more glutamine (Figure 1A), showing that mTORC1
activation stimulates the uptake of this nutrient. In addition,
re-expression of Tsc2 in Tsc2/ cells reduced glutamine uptake
(Figure S1A available online). Similarly, mTORC1 inhibition with
rapamycin resulted in decreased glutamine uptake in MEFs (Fig-
ure 1A). The decrease in glutamine uptake was significantly
reduced after 6 hr of rapamycin treatment when compared to
control (data not shown). To further confirm the role of mTORC1
on glutamine uptake, we used human embryonic kidney (HEK)
293T cells stably expressing either RHEB-WT or a constitutively
active mutant (S16H) of RHEB. Increased mTORC1 signaling, asevidenced by sustained phosphorylation of S6K1 and its target
rpS6, was observed in RHEB-expressing cells (Figure S1B).
The activation of the mTORC1 pathway nicely correlated with
an increase in glutamine consumption, therefore confirming
that changes in mTORC1 signaling are reflected in cellular gluta-
mine uptake (Figure S1B). To determine whether the modulation
of glutamine uptake by the mTORC1 pathway occurs in cancer
cells, we examined glutamine uptake rates in conditions of
mTORC1 inhibition in human epithelial tumor cell lines, including
the colon carcinoma DLD1 and the prostate cancer DU145.
Rapamycin treatment resulted in decreased proliferation (data
not shown) and yielded a decreased glutamine uptake in both
cell lines (Figure 1B and data not shown). Glutamine is the major
nitrogen donor for the majority of ammonia production in cells
(Figure 1C) (Shanware et al., 2011). Consistent with decreased
glutamine uptake, we found that ammonia levels were also
diminished after rapamycin treatment (Figure S1C).
Next, to examine the fate of glutamine in conditions of
mTORC1 inhibition, we used gas chromatography/mass spec-
trometry (GC/MS) analysis to monitor the incorporation of uni-
formly labeled [U-13C5]-glutamine into TCA-cycle intermediates.
Direct glutamine contribution to aKG (m+5), succinate (m+4),
malate (m+4), and citrate (m+4) was decreased in rapamycin-
treated cells (Figure S1D), indicating that rapamycin impairs
glutamine oxidation and subsequent carbon contribution into
the TCA cycle.
To test whether glutamine uptake or glutamine conversion is
limiting, we measured the intracellular levels of glutamine and
glutamate in DLD1 cells. Increased levels of glutamine and/or
glutamate will show that the catalyzing enzyme activity is limiting
and not glutamine transport itself (Fendt et al., 2010). Rapamycin
treatment resulted in increased intracellular levels of both gluta-
mine and glutamate, showing that glutamate-to-aKG conversion
is the critical limiting reaction (Figures 1D and 1E). To further
confirm the implication of the glutamate-catalyzing reaction,
we also measured aKG levels. If glutamate conversion is indeed
critical, we expect no alteration in aKG levels. This is expected
because aKG is downstream of the potentially limiting glutamate
conversion step, and it has been shown that product metabolite
concentrations of limiting metabolic enzymes stay unaltered,
whereas the substrate metabolite concentrations change to
keep metabolic homeostasis (Fendt et al., 2010). We found
that aKG levels were unaltered after rapamycin treatment,
corroborating that the limiting enzymatic step is glutamate con-
version (Figure 1F). To further confirm the limitation in glutamate-
to-aKG conversion, we measured flux through this reaction.
Strikingly, this flux was significantly reduced during rapamycin
treatment (Figure 1G). Additionally, the inhibition of mTORC1
resulted in increased glutamate secretion (Figure 1H), thus
confirming that the glutamate-to-aKG conversion step is a
major bottleneck in the glutamine pathway during rapamycin
treatment.
Glutamate conversion can be conducted by GDH (Figure 1C),
suggesting that the mTORC1 pathway potentially regulates this
enzyme. In agreement, rapamycin treatment resulted in
decreased GDH activity in DLD1 cells (Figure 1I). To exclude
that transaminases play a role in the mTORC1-induced regula-
tion of glutamine metabolism, we used aminooxyacetate (AOA)Cell 153, 840–854, May 9, 2013 ª2013 Elsevier Inc. 841
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Figure 1. The mTORC1 Pathway Regulates Glutamine Metabolism via GDH
(A and B) Glutamine uptake was determined in (A) Tsc2-WT and Tsc2/ MEFs treated with rapamycin and (B) DLD1 cells treated with rapamycin.
(C) A diagram showing the enzymes involved in glutamine anaplerosis and the inhibitors used in this study (see text for more details).
(D–F) Intracellular levels of glutamine (D), glutamate (E), and aKG (F) in DLD1 cells treated with rapamycin.
(G) Glutamate-to-aKG flux was determined in DLD1 cells treated with rapamycin.
(H) Glutamate secretion rates in DLD1 cells treated as in (B).
(I) GDH activity in DLD1 cells treated with rapamycin. EGCG was used as a positive control.
(J) Alanine levels were determined in DLD1 cells treated with rapamycin or AOA.
AU: arbitrary units. The mean is shown; error bars represent SEM (n > 3). See also Figure S1.at a concentration shown to effectively inhibit the two predomi-
nant transaminases, alanine aminotransferase (ALT) and aspar-
tate aminotransferase (AST) (Figure 1C) (Wise et al., 2008), or
rapamycin in the presence of a-15N-labeled glutamine. Subse-
quently, we measured 15N-labeling patterns and metabolite
levels of alanine, an amino acid that is predominately produced
by a transaminase-catalyzed reaction (Possemato et al., 2011).
We found that AOA dramatically decreased 15N contribution
and metabolite levels of alanine, whereas rapamycin only mildly
affected the 15N contribution to this amino acid and showed no
effect on alanine levels compared to the control condition842 Cell 153, 840–854, May 9, 2013 ª2013 Elsevier Inc.(Figures 1J and S1E). In conclusion, these data demonstrate
that GDH, not transaminases, plays a major role in the regulation
of glutamine metabolism downstream of mTORC1.
mTORC1 Controls GDH Activity by Repressing SIRT4
As our results show that mTORC1 regulates GDH, we sought to
identify the molecular mechanism. SIRT4 is a negative regulator
of GDH activity through ADP-ribosylation (Haigis et al., 2006),
thus suggesting that mTORC1 potentially controls this step of
glutamine metabolism via SIRT4. To test this possibility, we first
assessed the ADP-ribosylation status of GDH by introducing
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Figure 2. mTORC1 Controls Glutamate Dehydrogenase Activity by Repressing SIRT4
(A) DLD1 cells were treated with rapamycin followed by analysis of mono-ADP-ribosylated GDH as described in the Experimental Procedures. DLD1 cells stably
expressing SIRT4-HA were used as a positive control.
(B) GDH activity was determined in Tsc2/MEFs transfected with a nontargeting control siRNA (NTC) or two independent siRNAs against SIRT4, then treated
with rapamycin for 24 hr.
(C–F) SIRT4 protein levels in whole-cell lysates from (C) Tsc2-WT, Tsc2/ MEFs and PTEN-WT, PTEN/ MEFs treated as in (A); (D) DLD1 and DU145 cells
treated as in (A); (E) Tsc2/MEFs transfected with a nontargeting control (NTC) siRNA or siRNAs targeting either raptor or rictor; and (F) the liver of Tsc2+/mice
treated with rapamycin.
The mean is shown; error bars represent SEM (n > 3). See also Figure S2.biotin-labeled NAD followed by immunoprecipitation with avidin-
coated beads. Rapamycin treatment led to an increase in the
mono-ADP-ribosylation status of GDH, similar to that observed
in cells stably expressing SIRT4 (Figure 2A). Importantly, we
found that the knockdown of SIRT4 abrogated the rapamycin-
induced decrease in the activity of GDH (Figures 2B and S2A).
Strikingly, SIRT4 protein levels were increased upon mTORC1
inhibition in MEFs (Figure 2C). This regulation was confirmed in
both DLD1 and DU145 cells (Figure 2D). Remarkably, rapamycin
potently increased SIRT4 levels after 6 hr of treatment (Fig-
ure S2B), correlating with reduced glutamine consumption at
the same time point (data not shown). In contrast, SIRT4 levels
were not influenced by the treatment of MEFs with U0216, aninhibitor of MEK1/2 in the MAPK pathway (Figure S2C). All other
mTOR catalytic inhibitors tested in Tsc2/MEFs also resulted in
increased SIRT4 protein levels (Figure S2D). To evaluate a
potential regulation of SIRT4 by mTORC2, we performed RNA
interference (RNAi) experiments of either raptor or the mTORC2
component rictor in Tsc2/ MEFs. The knockdown of raptor,
but not rictor, was sufficient to increase SIRT4 protein levels,
confirming the role of the mTORC1 pathway in the regulation
of SIRT4 (Figure 2E). To investigate whether mTORC1 regulation
of SIRT4 occurs in tumor samples, a TSC-xenograft model was
used. We injected the TSC2/ rat leiomyoma cell line ELT3
expressing either an empty vector (V3) or TSC (T3) in the flank
of nude mice. SIRT4 levels were dramatically increased inCell 153, 840–854, May 9, 2013 ª2013 Elsevier Inc. 843
TSC2-expressing tumors compared to empty vector samples
(Figure S2E). In addition, we assessed the levels of SIRT4 in
both ELT3 xenograft tumors and mouse Tsc2+/ liver tumors
after rapamycin treatment. As expected, these tumor samples
exhibited robust elevation of SIRT4 after rapamycin treatment
(Figures 2F and S2F). Thus, these data demonstrate that the
mTORC1 pathway represses SIRT4 in several tumor systems.
CREB2 Regulates the Transcription of SIRT4
in an mTORC1-Dependent Fashion
We next asked whether the mTORC1-dependent regulation of
SIRT4 occurred at the mRNA level. Quantitative RT-PCR results
show that rapamycin treatment significantly increased the
expression of SIRT4 messenger RNA (mRNA) in Tsc2/ MEFs
(Figure 3A). SIRT4 mRNA levels were dramatically reduced in
Tsc2/ MEFs compared to their WT counterpart (Figure 3B).
Similar results were obtained from transcriptional profiling anal-
ysis of the SIRT4 gene from a previously published data set
(GSE21755) (Figure 3C) (Du¨vel et al., 2010). Altogether, our
data demonstrate that mTORC1 negatively regulates the tran-
scription of SIRT4.
To identify candidate transcription factors regulating
SIRT4, we analyzed the nucleotide sequence of the human
SIRT4 promoter region. We used the TFSEARCH program, a
computer algorithm available at http://mbs.cbrc.jp/research/
db/TFSEARCH.html, and identified21potential transcription fac-
tors thatmaybinddirectly to andmodulateSIRT4promoter activ-
ity (see Table S1). Interestingly, among these potential hits,
CREB2 is involved in the control of many metabolic processes,
including glucose, lipid, and amino acid metabolism (Yoshizawa
et al., 2009; Wang et al., 2010a; Ye et al., 2010). Moreover, a
sequence in the human SIRT4 promoter displayed significant
homology with the canonical CREB recognition motif TGAY-
GYAA (Y = C or T) (Figure 3D). To determine whether CREB2 is
involved in themTORC1-dependent regulation of SIRT4, we per-
formed RNAi experiments. The silencing of CREB2 abolished the
rapamycin-induced expression of SIRT4 (Figures 3E and S3A).
Remarkably, the knockdown of CREB1 did not affect the upregu-
lation of SIRT4 upon mTORC1 inhibition, thus demonstrating the
specificity of CREB2 to induceSIRT4 (Figure S3B).Moreover, the
knockdown of CREB2 significantly abrogated the rapamycin-
induced increase in the activity of the SIRT4 promoter, as deter-
mined by using a pGL3 luciferase reporter containing the putative
CREB2-binding sequence (Figure 3F). Finally, chromatin immu-
noprecipitation (ChIP) assays revealed that CREB2 binds SIRT4
during conditions of mTORC1 inhibition (Figure 3G).
mTORC1 Regulates the Stability of CREB2
We next investigated whether the mTORC1 pathway regulates
CREB2. Although we did not observe major changes in Creb2
mRNA in normal growth conditions (Figure S4A), mTORC1 inhi-
bition resulted in accumulation of CREB2 protein levels by 2 hr of
rapamycin treatment (Figure 4A). U0126 failed to cause the
accumulation of CREB2 (Figure S4B). In contrast, CREB1 protein
levels were not affected after 24 hr of rapamycin treatment (Fig-
ure S4C). As observed for SIRT4, mTOR catalytic inhibitors, and
the specific knockdown of mTOR, resulted in upregulation of
CREB2 protein levels (Figures S4D and S4E). CREB2 is upregu-844 Cell 153, 840–854, May 9, 2013 ª2013 Elsevier Inc.lated in diverse cell types as a response to a variety of stresses,
including hypoxia, DNA damage, and withdrawal of GFs,
glucose, and aa (Che´rasse et al., 2007; Rouschop et al., 2010;
Yamaguchi et al., 2008; Whitney et al., 2009). Interestingly,
mTORC1 is negatively regulated by all of these environmental in-
puts (Zoncu et al., 2011). Because mTORC1 signaling in Tsc2/
MEFs is insensitive to serum deprivation, we assessed the role of
aa withdrawal and restimulation on CREB2 levels. As shown in
Figure 4B, CREB2 accumulated upon aa deprivation and was
decreased following aa readdition. This phenomenon required
the action of the proteasome as MG132 efficiently blocked
CREB2 degradation following aa readdition. Importantly, we
found that mTORC1 inhibition abrogated the aa-induced
decrease of CREB2 (Figure 4B). Similarly, MG132 protected
CREB2 levels after insulin stimulation in Tsc2-WT MEFs
(Figure S4F). These data suggest that mTORC1 regulates the
stability of the CREB2 protein in our model. Consistent with
this, cycloheximide (CHX) treatment revealed that the increase
in CREB2 abundance following mTORC1 inhibition is due to
increased CREB2 half-life (Figure 4C). Taken together, our data
demonstrate that CREB2 accumulation following mTORC1 inhi-
bition primarily occurs through a posttranscriptional mechanism.
mTORC1 Activation Promotes the Binding of CREB2
to bTrCP and Modulates CREB2 Ubiquitination
Next, we attempted to identify the E3 ubiquitin ligase that might
be responsible for CREB2 turnover. Consistent with a recent
study, we found CREB2 to bind the E3 ligase bTrCP (Frank
et al., 2010). However, other related E3 ligases including
Fbxw2, Fbxw7a, and Fbxw9 did not bind to CREB2 (data not
shown). The interaction of CREB2 with Flag-bTrCP1 was
enhanced in the presence of insulin and was abolished by rapa-
mycin pretreatment (Figure 4D). Importantly, insulin treatment
promoted the ubiquitination of CREB2 in an mTORC1-depen-
dent fashion (Figure 4E). Altogether, our results support the
notion that the mTORC1 pathway regulates the targeting of
CREB2 for proteasome-mediated degradation. bTrCP binds
substrates via phosphorylated residues in conserved degrada-
tion motifs (degrons), typically including the consensus
sequence DpSGX(n)pS or similar variants. We found an evolu-
tionarily conserved putative bTrCP-binding site (DSGXXXS) in
CREB2 (Figure 4F). Interestingly, we noted a downward mobility
shift in CREB2 protein with mTORC1 inhibition, consistent with a
possible decrease in the phosphorylation of CREB2 (Figure 4A).
Frank et al. (2010) showed that phosphorylation of the first serine
in the degron motif corresponding to Ser218 is required for the
CREB2/bTrCP interaction, and this modification acts as a prim-
ing site for a gradient of phosphorylation events on five proline-
directed residue codons (T212, S223, S230, S234, and S247)
that is required for CREB2 degradation during the cell-cycle pro-
gression (Frank et al., 2010). Consistent with these observations,
we found that the mutation of the five residues to alanine
(5A mutant) resulted in strong stabilization of CREB2, compara-
ble to the serine-to-alanine mutation on the priming Ser218
phosphorylation site (Figure S4G). Single point mutations on
each residue did not significantly increase stability compared
with CREB2-WT (data not shown). Finally, to confirm the role
of these five residues in the regulation of SIRT4, we expressed
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Figure 3. SIRT4 Is Regulated at the mRNA Level in an mTORC1-Dependent Fashion
(A) SIRT4 mRNA levels in Tsc2/ MEFs treated with rapamycin for 24 hr.
(B) SIRT4 mRNA levels in Tsc2/ and Tsc2-WT MEFs as in (A).
(C) Boxplots of SIRT4 expression in Tsc2-WT (blue) and Tsc2/ MEFs without (red) or with (green) rapamycin treatment.
(D) CREB-binding consensus motif identified on several CREB target gene promoters and the human SIRT4 gene promoter. The putative CREB recognition
sequence on the human SIRT4 promoter was aligned with other established CREB recognition sequences.
(E) SIRT4 mRNA levels in Tsc2/ MEFs transfected with nontargeting siRNA (NTC) or with two independent siRNAs against CREB2. Cells were treated with
rapamycin for 24 hr.
(F) Normalized luciferase light units of CREB2 knocked down Tsc2/ transfected with a pGL3-luciferase reporter construct or with pGL3-SIRT4. Twenty-four
hours after transfection, cells were treated with DMSO or rapamycin for 24 hr (*p < 0.05).
(G) Tsc2/ MEFs were incubated in the presence or absence of rapamycin and were then harvested for ChIP analysis with an anti-CREB2 antibody or
preimmune IgG. Specific primers were used to amplify SIRT4. Input chromatin was diluted to 1:1000. a-RNA polymerase II (Pol II) was used as a positive control.
All PCR products were resolved by 2% agarose electrophoresis.
The mean is shown; error bars represent SEM (n > 3). See also Figure S3.
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Figure 4. mTORC1 Regulates the Stability of CREB2
(A) Immunoblot analysis of CREB2 in Tsc2/ MEFs treated with rapamycin. Cells were harvested at the indicated time points. The right panel shows the
quantification of band intensities. CREB2 bands were normalized to a-tubulin, then normalized to the t = 0 time point.
(B) Tsc2/ MEFs were amino acid (aa) and serum starved for 18 hr and pretreated with the indicated drugs for 30 min, followed by addition of aa for 2 or 6 hr.
Protein lysates were resolved by immunoblot with the antibodies indicated. The asterisk (*) denotes a nonspecific band.
(C) Tsc2-WT MEFs were serum starved for 18 hr and were pretreated with rapamycin or DMSO for 30 min. One hundred nanomoles of insulin with 20 mg/ml
cycloheximide (CHX) were added to cells before harvesting. The bottom panel shows the quantification of band intensities. CREB2 bands were normalized to
GAPDH, then normalized to the t = 0 time point.
(D) HEK293E cells were transfected with constructs coding Flag-bTrCP1. Twenty-four hours after transfection, cells were serum starved for 18 hr and pretreated
with rapamycin for 30 min. One hundred nanomoles of insulin were then added to cells for 2 hr. Total protein lysates were subjected to immunoprecipitation with
anti-Flag M2 antibody.
(E) Flag-CREB2 was expressed in HEK293E cells together with His-Ub. Cells were serum starved for 18 hr and treated with MG132 for 4 hr. Then, cells were
pretreated with either DMSO or rapamycin for 30 min. One hundred nanomoles of insulin were added for 6 hr. His-ubiquitinated proteins were pulled down with
Ni-NTA agarose and analyzed by immunoblotting.
(legend continued on next page)
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Figure 5. SIRT4 Represses Bioenergetics
and Proliferation
(A and B) Glutamine uptake was determined in (A)
Tsc2/ MEFs stably expressing SIRT4 or vector
control and (B) DLD1 cells expressing SIRT4 or
vector control.
(C) The ATP/ADP ratio was measured in Tsc2/-
control or SIRT4-expressing MEFs treated with or
without oligomycin (5 mg/ml).
(D) Cell viability of control or SIRT4-expressing
Tsc2/ MEFs deprived of glucose and supple-
mented with DM-aKG (7 mM) or pyruvate (1 mM)
for 48 hr.
(E and F) Growth curves of DLD1 (E) and DU145 (F)
cells stably expressing SIRT4 or vector control.
Cells were cultured in standard media lacking
pyruvate, and DM-aKG was added to media as
indicated. Cell number was measured every 24 hr
for 4 consecutive days.
The mean is shown; error bars represent SEM
(n > 3). See also Figure S5.Flag-CREB2-WT, S218A, and 5A in serum-starved HEK293E. As
shown in Figure 4G, insulin addition to cells expressing an empty
vector (EV) resulted in decreased SIRT4 levels, a phenomenon
abrogated by rapamycin pretreatment. SIRT4 levels were upre-
gulated in cells expressing Flag-CREB2-WT, S218A, and 5A
when compared to control cells. However, only the expression
of either S218A and 5A mutants was able to block the insulin-
mediated decrease of SIRT4 (Figure 4G). Taken together,(F) Schematic of the conserved bTrCP degrons in CREB2 across multiple species.
(G) CREB2 mutants were expressed in HEK293E cells. These cells were serum starved for 18 hr and pre
nanomoles of insulin were added to the media for 8 hr.
See also Figure S4.
Cell 153, 840–our results demonstrate that the
mTORC1 pathway promotes the destabi-
lization of CREB2 to downregulate SIRT4
expression.
SIRT4 Represses Bioenergetics
and Cell Proliferation
We observed that glutamine utilization is
repressed by rapamycin treatment (Fig-
ure 1), and SIRT4 is induced by mTORC1
inhibition (Figure 2). Thus, we tested
whether SIRT4 itself directly regulates
cellular glutamine uptake. The stable
expression of SIRT4 resulted in the
repression of glutamine uptake in Tsc2/
MEFs and DLD1 cells (Figures 5A and
5B). Glucose uptake was not affected by
SIRT4 expression (data not shown).
Because glutamine can be an important
nutrient for energy production, we exam-
ined ATP levels in SIRT4-expressing
cells. Consistent with reduced glutamine
consumption, the expression of SIRT4 in
Tsc2/ cells resulted in a decreased
ATP/ADP ratio compared to control cells (Figure 5C). Cells pro-
duce ATP via glycolysis and oxidative phosphorylation
(OXPHOS). To test the contribution of mitochondrial metabolism
versus glycolysis to ATP, we measured the ATP/ADP ratio after
the treatment with oligomycin, an inhibitor of ATP synthesis
from OXPHOS. Importantly, the difference of the ATP/ADP ratio
between control and SIRT4-expressing cells was abrogated by
oligomycin (Figure 5C), further demonstrating that SIRT4 maytreated with rapamycin for 30 min. One hundred
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Figure 6. SIRT4 Suppresses TSC-Tumor Development
(A) Soft agar assays with Tsc2/ or Tsc2-WT MEFs expressing control vector or SIRT4.
(B) Kaplan-Meier plot of the percentage of tumor-free mice after inoculation with Tsc2/ p53/ MEFs expressing control or SIRT4 vectors (n = 8). *p < 0.05.
(legend continued on next page)
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repress the ability of cells to generate energy frommitochondrial
glutamine catabolism.
Mitochondrial glutamine catabolism is essential for energy
production and viability in the absence of glucose (Yang et al.,
2009; Choo et al., 2010). Thus, we examined the effect of
SIRT4 on the survival of Tsc2/ MEFs during glucose depriva-
tion. Control cells remained viable following 48 hr of glucose
deprivation. Conversely, SIRT4-expressing cells showed a dra-
matic increase in cell death under glucose-free conditions, and
this increase was rescued by the addition of the cell-permeable
dimethyl-aKG (DM-aKG) (Figure 5D). In contrast, the expression
of SIRT4 did not affect the viability of glucose-deprived Tsc2-WT
MEFs (Figure S5A). Glucose deprivation also induced death of
the human DU145 cancer cell line stably expressing SIRT4
(data not shown).
Glutamine is an essential metabolite for proliferating cells, and
many cancer cells exhibit a high rate of glutamine consumption
(DeBerardinis et al., 2007). Thus, decreased glutamine uptake
in DLD1 and DU145 cancer cells expressing SIRT4 might result
in decreased proliferation. Indeed, these cells grew significantly
slower than did control cells. Remarkably, DM-aKG completely
abrogated the decreased proliferation of SIRT4-expressing cells
(Figures 5E and 5F), suggesting that repressed glutamine meta-
bolism drove the reduced proliferation of cells expressing SIRT4.
The expression of SIRT4 also slowed the proliferation of Tsc2/
MEFs but did not affect Tsc2-WT MEFs (Figures S5B and S5C).
Finally, to rule out that the effect on proliferation was due to aber-
rant localization and to off-target effects of the overexpressed
protein, we examined the localization of HA-SIRT4. We found
that SIRT4 is colocalized with the MitoTracker, a mitochon-
drial-selective marker (Figure S5D). Taken together, these data
demonstrate that SIRT4 is a critical negative regulator of mito-
chondrial glutamine metabolism and cell proliferation.
SIRT4 Represses TSC-Tumor Development
Recent studies have demonstrated a major role of glutamine
metabolism indrivingoncogenic transformation ofmanycell lines
(Gao et al., 2009;Wang et al., 2010b). Because SIRT4 expression
represses glutamine uptake and cell proliferation (Figure 5), we
hypothesized that it could affect tumorigenesis. To test this
idea, we used an anchorage-independent growth assay to
assess the role of SIRT4 in cell transformation. SIRT4 expression
reduced the ability of Tsc2/ p53/MEFs to grow in soft agar.
However, the expression of SIRT4 in Tsc2+/+ p53/ did not
impair their colony-formation properties (Figure 6A). Next, we
performed xenograft assays to investigate the impact of SIRT4
in cell growth in vivo. We inoculated Tsc2/ p53/ and
Tsc2+/+ p53/MEFs stably expressing SIRT4 or vector control,(C) Tumor volume and weight were measured.
(D) Immunohistochemical analysis of Ki-67 and representative H&E staining (orig
(E) Quantification of Ki-67 staining in tumors from (D).
(F) Boxplots indicating significantly lower expression of SIRT4 gene in blad
corresponding normal (*p < 0.05).
(G) Ranked SIRT4 expression in a breast carcinoma data set of 195 tumors.
(H) Kaplan-Meier curve comparing time to metastasis between breast carcinom
expression (p = 0.02, log-rank test).
The mean is shown; error bars represent SEM (n > 3). See also Figure S6.subcutaneously and bilaterally, into nude mice (n = 8 per group).
Tumor incidence in mice injected with Tsc2+/+ p53/MEFs was
not affected by SIRT4 (data not shown). Conversely, in the
Tsc2/ p53/ cohort, SIRT4 reduced tumor incidence by
20 days at median (Figure 6B). Furthermore, at post-inoculation
day 80, mice injected with SIRT4 cells had a mean tumor volume
of 246.1 ± 124.1 mm3, whereas mice injected with control cells
had a mean tumor volume of 589.1 ± 101.5 mm3 (p < 0.05) (Fig-
ure 6C). As expected, SIRT4 and control tumors were immunore-
active for phospho-S6 (Figure 6D) and expressedHA-SIRT4 (Fig-
ure S6). Furthermore, SIRT4 expression in Tsc2/ p53/MEFs
resulted in reduction of Ki-67 positivity by 60% (Figure 6E),
consistent with the finding that SIRT4 inhibits the proliferation
of these cells in vitro (Figure S5B). Finally, we performed a
comprehensive meta-analysis of SIRT4 expression in human
tumors and found significantly lower expression levels of
SIRT4, relative to normal tissue, in bladder, breast, colon, gastric,
ovarian, and thyroid carcinomas (Figure 6F). Interestingly, loss of
SIRT4 expression showed a strong association with shorter time
to metastasis in patients with breast cancer (Figures 6G and 6H).
Altogether, these data strongly suggest that SIRT4 delays tumor-
igenesis regulated by the mTORC1 pathway.
The Pharmacologic Inhibition of Glutamine Anaplerosis
Synergizes with Glycolytic Inhibition to Induce the
Specific Death of mTORC1-Hyperactive Cells
The activation of mTORC1 leads to glucose and glutamine
addiction as a result of increased uptake and metabolism of
these nutrients (Choo et al., 2010; Du¨vel et al., 2010) (Figure 1).
These observations suggest that targeting this addiction offers
an interesting therapeutic approach for mTORC1-driven tumors.
The alkylating agent, mechlorethamine (Mechlo), incites cell
toxicity in part by the inhibition of the GAPDH step of glycolysis
via poly-ADP ribose polymerase (PARP)-dependent cellular con-
sumption of cytoplasmic NAD+. The ultimate consequence is
glycolytic inhibition, thus mimicking glucose deprivation (Zong
et al., 2004). Treatment of Tsc2/MEFs with Mechlo decreased
both NAD levels and lactate production (Figure 7A and data not
shown). The decrease in NAD+ levels was rescued by addition of
DPQ (Figure 7A), a PARP inhibitor (Zong et al., 2004). We next
tested the ability of glutamine inhibition to determine the sensi-
tivity of Tsc2/ MEFs to Mechlo. As shown in Figure 7B, the
treatment with EGCG, a GDH inhibitor (Figure 1G), potently syn-
ergized with Mechlo to kill Tsc2/MEFs with the greatest effect
observed at 30 mM (Figure 7B). As a result, this combination
dramatically increased the cleavage of PARP, an apoptotic
marker (Figure 7E). Similarly, glutamine deprivation sensitized
Tsc2/ MEFs to Mechlo (data not shown). The RNAi-mediatedinal magnification, 203).
der, breast, colon, gastric, ovarian, and thyroid carcinomas compared to
as with the lowest (<25th percentile) versus highest (>25th percentile) SIRT4
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Figure 7. The Combination of Glutamine Metabolism Inhibitors with Glycolytic Inhibition Is an Effective Therapy to Kill Tsc2/
and PTEN/ Cells
(A) NAD levels in Tsc2/ MEFs treated with the indicated doses of mechlorethamine with or without DPQ for 24 hr.
(B) Tsc2/MEFs transducedwith an empty vector were given the indicated doses ofmechlorethamine with or without EGCG (50 mM). Cell viability wasmeasured
48 hr post-treatment via PI exclusion.
(C) Tsc2/ MEFs re-expressing Tsc2 were treated as in (B).
(D) Tsc2/MEFswere transfected with a nontargeting control siRNA (NTC) or siRNA targeting GDH. Twenty-four hours post-transfection, cells were treated with
20 mM of mechlorethamine, and cell viability was determined 48 hr later post-treatment.
(legend continued on next page)
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knockdown of GDH also synergized withMechlo to induce death
of Tsc2/ MEFs (Figure 7D). Importantly, at these concentra-
tions, the combination did not induce death of a Tsc2-rescued
cell line (Figure 7C).
Because the metabolic properties of cells with activated
mTORC1 by Tsc2 deficiency can be efficiently targeted, we
also examined other cell types in which mTORC1 is hyperactive
by the loss of PTEN. We found that the combination of Mechlo
and EGCG was also effective in inducing specific toxicity of
PTEN/MEFs, whereas PTEN+/+ MEFs were not affected (Fig-
ures S7A and S7B). In addition, the PTEN-deficient human pros-
tate adenocarcinoma cell line LNCaP was also sensitive to treat-
ment with Mechlo and EGCG (Figure 7F). This effect was
specifically due to lack of TCA-cycle replenishment as pyruvate
supplementation completely reversed the synergistic effect (Fig-
ure 7F). The combination of Mechlo with the GLS1 inhibitor
BPTES (Figure 1G) also resulted in decreased viability of Tsc2/
cells but not of Tsc2-reexpressing cells (Figures S7C and S7D).
Again, death in Tsc2/ cells was rescued with pyruvate or
OAA (Figure S7E). To further investigate whether the potent
cell death in Tsc2/ was restricted to Mechlo, we used 2-DG,
a glycolytic inhibitor. The combination of 2-DG with either
EGCG or BPTES resulted in enhanced cell death of Tsc2/
MEFs compared to single-agent treatments (Figure S7F). This ef-
fect was also specific to Tsc2/ cells, as this combination was
less toxic in Tsc2-re-expressing MEFs (Figure S7G). Taken
together, our results demonstrate that the combination treat-
ments aimed at inhibiting glycolysis and glutaminolysis potently
synergize to kill cells with hyperactive mTORC1 signaling.
DISCUSSION
Here, we define an mTORC1-regulated pathway that controls
glutamine-dependent anaplerosis and energy metabolism (Fig-
ure 7G). We discovered that the mTORC1 pathway regulates
glutamine metabolism by promoting the activity of GDH (Figures
1, 2, and 3). We show that this regulation occurs by repressing
the expression of SIRT4, an inhibitor of GDH (Figures 2 and 3).
Molecularly, this is the result of mTORC1-dependent protea-
some-mediated degradation of the SIRT4 transcriptional regu-
lator CREB2 (Figure 4). Interestingly, the modulation of CREB2
levels correlates with increased sensitivity to glutamine depriva-
tion (Ye et al., 2010; Qing et al., 2012), fitting with our model of
glutamine addiction as a result of mTORC1 activation (Choo
et al., 2010). Our data suggest that mTORC1 promotes the bind-
ing of the E3 ligase bTrCP to CREB2 (Figure 4D), promoting
CREB2 degradation by the proteasome (Figure 4E). A previous
study has demonstrated that five residues in CREB2 located
next to the bTrCP degron are required for its stability (Frank
et al., 2010). Accordingly, the mutation of these residues to
alanine resulted in stabilization of CREB2 and SIRT4 following
insulin- and aa-dependent mTORC1 activation (Figure 4G).
Future work is aimed at determining whether mTORC1 and/or(E) Immunoblot analysis of cleaved PARP in Tsc2/ MEFs treated with mechlore
(F) Cell viability of LNCaP cells treated with mechlorethamine or EGCG or the co
(G) Schematic of the regulation of SIRT4 and glutamine metabolism by the mTO
The mean is shown; error bars represent SEM (n > 3). See also Figure S7.downstream kinases are directly responsible for the multisite
phosphorylation of CREB2.
The identification of CREB2 as an mTORC1-regulated tran-
scription factor increases the repertoire of transcriptional regula-
tors, including HIF1a (glycolysis), Myc (glycolysis), and SREBP1
(lipid biosynthesis), that are modulated by this pathway (Du¨vel
et al., 2010; Yecies and Manning, 2011). The oncogene Myc
has also been linked to the regulation of glutamine metabolism
by increasing expression of the surface transporters ASCT2
and SN2 and the enzyme GLS. Thus, enhanced activity of Myc
correlates with increased glutamine uptake and glutamate
production (Wise et al., 2008; Gao et al., 2009). Our findings
describe an important level of control to this metabolic node as
shown by themodulation of the glutamate-to-aKG flux (Figure 2).
This regulation is particularly relevant as some cancer cells pro-
duce more than 50% of their ATP by oxidizing glutamine-derived
aKG in the mitochondria (Reitzer et al., 1979). Therefore, these
studies support the notion that Myc and CREB2/SIRT4 coop-
erate to regulate the metabolism of glutamine to aKG. Interest-
ingly, Myc function may also be regulated by mTORC1 (West
et al., 1998), although the mechanism is not known. Thus,
besides controlling CREB2/SIRT4/GDH, mTORC1 might also
influence the Myc/GLS axis, explaining the decrease of gluta-
mine uptake observed in rapamycin-treated cells (Figure 1).
Our studies reveal the important impact of SIRT4 function on
glutamine anaplerosis and tumor cell metabolism. Importantly,
SIRT4 expression is decreased in a panel of human cancers,
and we show that its expression results in decreased cell trans-
formation and tumor development in a TSC-xenograft model
(Figure 6). SIRT3 also represses tumorigenesis by regulating
both genomic instability and the Warburg effect (Kim et al.,
2010; Finley et al., 2011). Thus, these two mitochondrial sirtuins
seem to function coordinately to modulate cell proliferation by
controlling the two major nutrient sources required for tumor
cell anabolism.
Glutamine is the main precursor for GSH synthesis despite
sufficient glucose and oxygen levels, and the pharmacologic
inhibition of GLS results in increased reactive oxygen species
(ROS) and decreased proliferation (Le et al., 2012). Therefore,
the importance of the glutamine pathway as a substrate for the
TCAcycle, or as a regulator of redox homeostasis,maybe impor-
tant for cancer cell adaption and survival. As a proof of concept,
we show that inhibition of glutamine metabolism synergizes with
glycolytic attenuation to induce robust death of Tsc2/ cells,
whereas their normal counterparts are not sensitive to dual
inhibition. EGCG, an antioxidant found in green tea extracts
and a potent inhibitor of GDH (Li et al., 2006), is already in several
clinical trials as an anticancer agent and has been shown to be
effective in limiting tumor growth in mice (Li et al., 2006; Khan
and Mukhtar, 2008; Xu et al., 1992, Zhang et al., 2010).
Our findings shed light on potential therapeutic strategies for
cancers and genetic disorders, such as TSC and LAM, charac-
terized by deregulation of the mTORC1 pathway. Recently,thamine (30 mM) or EGCG (50 mM) or the combination of both drugs for 24 hr.
mbination of both drugs. Pyruvate was added to the media as indicated.
RC1 pathway.
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rapamycin analogs showed efficacy in reducing the size of
angiomyolipomas in clinical trials of TSC (Bissler et al., 2008).
Moreover, these agents stabilized respiratory function and
were associated with improvement in quality of life of LAM
patients (McCormack et al., 2011). However, although the
response to rapamycin was significant, effects were cytostatic,
and tumor growth was observed after therapy cessation (Bissler
et al., 2008), highlighting the need to develop specific agents for
therapeutic intervention. TSC tumors display low fluorodeoxy-
glucose (FDG) uptake in PET scanning (Young et al., 2009),
suggesting that a source other than glucose fuels these tumors
for survival; glutamine is likely to be such a source. Interestingly,
we observed increased cell death of patient-derived LAM cells
cultured under glutamine deprivation (data not shown). There-
fore, we speculate that targeted inhibition of glutaminolysis
may induce tumor cell toxicity in LAM patients.
In sum, our work illustrates thatmTORC1 inhibits the activity of
GDH by regulating the transcription of SIRT4. Moreover, our
studies support the rationale of using PET imaging by 4-fluoro-
glutamine for mapping glutaminolytic tumors (Lieberman et al.,
2011) and, importantly, the development of drugs targeting
glutamine metabolism as cancer therapy.
EXPERIMENTAL PROCEDURES
Cell Lines and Culture
Tsc2/ p53/ and Tsc2+/+ p53/ MEFs were kindly provided by Drs.
Brendan Manning and David Kwiatkowski (Harvard Medical School). ELT3
cells were provided by Dr. Cheryl Walker (University of Texas). All other cell
lines were obtained from the American Type Culture Collection (ATCC).
MEFs, ELT3, HEK293T, and HEK293E cells were cultured in DMEM. DLD1,
LNCaPs, and DU145 cells were cultured in RPMI media (Mediatech). DMEM
or RPMI were supplemented with 10% FBS (dialyzed for deprivation experi-
ments—GIBCO). All DMEM lacking glucose, aa, L-glutamine, or combinations
were made from formulations provided by Sigma. All extra energetic additives
that are often added to some DMEM formulations such as sodium pyruvate
and succinate were excluded.
Antibodies, Chemicals, and Plasmids
The antibodies used for this study are the following: Ki-67 antibody is from
BioGenex. p53, HIF-1a, Raptor, p70, 389(P) p70, S6(P), Akt-473, Akt, a-tubulin,
4EBP1, PTEN, TSC2, 202(P)204(P) ERK1/2, ERK1/2, 51(P) eIF2a, CREB, and
cleaved PARP were all purchased from Cell Signaling Technologies. Antibody
to CREB2 was purchased from Santa Cruz, Inc. Antibody to GDH was pur-
chased from Abcam. SIRT4 and FLAG-M2were purchased from Sigma. Rictor
antibody was from Bethyl Laboratories. GAPDH antibody was purchased from
Ambion. PAR antibody was from Calbiochem. The following chemicals were
used in this study: rapamycin (Calbiochem), EGCG (Calbiochem), LY294002
(Calbiochem), cycloheximide (Calbiochem),methylpyruvate (Sigma), aminoox-
yacetate (Sigma), DM-a-ketoglutaric acid (Sigma), sodium pyruvate (Sigma),
mechlorethamine hydrochloride (Sigma), succinic acid (Sigma), glutamate
(Sigma), U0126 (Selleckchem), 3-methyladenine (Sigma), oligomycin (Calbio-
chem), insulin (Sigma), PI-103 (Selleckchem), MG132 (Sigma), DPQ (Santa
Barbara Technology), biotin-NAD+ (Trevigen), lipofectamine and RNAi MAX
(Invitrogen), and bromobimane (Sigma). SIRT4 was cloned into pBabe, TSC2
was cloned into pLPCX, and the TSC2-containing viruses were used to recon-
stitute Tsc2/ p53/MEFs. RHEB-WT and S16H were cloned into pLPCX2.
Cell-Number Measurements
Tsc2/ MEFs were grown on 6-well plates and treated as indicated, trypsi-
nized, and resuspended in PBS (pH 7.2) in a total of 10 ml. Cell number was
immediately analyzed on a Z2 Coulter Counter, and results were graphed in
Coulter AccuComp Software, gating between 12 mm and 30 mm.852 Cell 153, 840–854, May 9, 2013 ª2013 Elsevier Inc.Cell-Viability Measurements
All cell-viability experiments were conducted with propidium iodide (PI) exclu-
sion assay. In brief, PI was added to culture media (1 mg/ml) for 5 min prior to
collection. The media from each sample were collected, and then the plates
were washed briefly with saline. The saline was added to the media collection
tube, and then the remaining cells on the plate were detached with trypsin. The
cells were then collected and also put into the original media collection tube.
The entire tube, which now had the original media with saline wash and trypsi-
nized cells, was centrifuged, and the pellet was analyzed for PI exclusion via
fluorescence-activated cell sorting (FACS) (Beckon Dickinson). Additionally,
the cells were washed with media lacking glucose and all amino acids (1/2 vol-
ume of incubating media) prior to adding the experimental media, which con-
tained dialyzed FBS. For mechlorethamine experiments, cells were plated
overnight (15–18 hr), and media was changed for new media without pyru-
vate and with or without glutamine/glucose. Eight hours after the change, cells
were given different doses of mechlorethamine.
Cell Lysis and Immunoprecipitations
Cells washed once with cold PBS were solubilized on ice either in a regular
lysis buffer (40mMHEPES [pH 7.4], 1mMEDTA, 120mMNaCl, 10mM b-glyc-
erophosphate, 1 mM NaF, 1 mM Na3VO4, and 0.3% CHAPS) or in a low-salt
lysis buffer (40 mM HEPES [pH 7.4], 1 mM EDTA, 10 mM b-glycerophosphate,
1 mM NaF, 1 mM Na3VO4, and 0.3% CHAPS) supplemented with protease in-
hibitors (250 mM PMSF, 5 mg/ml pepstatin A, 10 mg/ml leupeptin, and 5 mg/ml
aprotinin). Cleared cell lysates were obtained by centrifugation at 10,000 rpm
for 10 min at 4C, and 0.7–1.2 mg of the lysates were used for immunoprecip-
itations. For this, cell lysates were incubated with primary antibodies for 2 hr at
4C followed by 1–2 hr of further incubation with 50% slurry of protein A/G-
sepharose presaturated with the lysis buffer. After rinsing three times with
the regular or low-salt lysis buffer, immunoprecipitated proteins were recov-
ered from the beads by boiling for 10 min in sample buffer and analyzed by
immunoblotting.
Labeling, Flux, and Metabolite-Level Measurements
Labeled tissue cultures were washed with saline, and metabolism was
quenched with 20C cold 65% methanol. After cell scraping in 65% meth-
anol, 20C cold chloroform was added, and the samples were vortexed at
4C to extract metabolites. Phase separation was achieved by centrifugation
at 4C.Methanol phase was separated and dried by applying constant airflow.
Dried metabolite samples were stored at 80C.
Metabolites were derivatized with methoxyamine (TS-45950 Thermo Scien-
tific) for 90 min at 40C and subsequently with N-(tert-butyldimethylsilyl)-N-
methyl-trifluoroacetamide, with 1% tert-butyldimethylchlorosilane (375934-
Sigma) for 60 min at 60C. Isotopomer distributions and metabolite levels
were measured with a 6890N GC system (Agilent Technologies) combined
with a 5975B Inert XL MS system (Agilent Technologies). Isotopomer distribu-
tions were analyzed with the Matlab-based software Metran (Antoniewicz
et al., 2007). Total ion counts were normalizedwith the internal standard norva-
line and cell number to yielded metabolite levels. Glutamate-to-aKG flux was
calculated based on glutamine and glutamate uptake or secretion rates.
NAD Measurement
To measure NAD levels, we used the NAD/NADH kit from Abcam (ab65348)
according to the manufacturer’s instructions.
In Vivo Manipulations
Two million Tsc2/ p53/ or Tsc2+/+ p53/MEFs stably expressing SIRT4-
HA or vector control pBabe were inoculated bilaterally into the posterior back
region of 6- to 8-week-old immunodeficient CD-1 nude mice (Taconic). Tumor
length, width, and depth were measured with a Vernier caliper by an investi-
gator blinded to the experimental conditions. 2.5 million V3 or T3 ELT3 cells
were inoculated bilaterally into the posterior back region of 6-week-old immu-
nodeficient CB17 SCID mice (Taconic). Tumors were harvested when they
reached 150 mm2. Seven-month-old Tsc2+/ mice in A/J background were
treated with either vehicle or rapamycin (Biomol) at a dose of 6 mg/kg every
other day for 3 days (two injections) (Figure 2F).
2.5 million ELT3 cells were inoculated bilaterally into the posterior back
region of 6-week-old immunodeficient CB17 SCID mice (Taconic). When
tumors reached 100 mm2, mice were randomly assigned to intraperitoneal
(i.p.) rapamycin (Biomol) at a dose of 1 mg/kg or sterile PBS three times per
week for 2 weeks (Figure S2F). The animal studies were approved by the An-
imal Care and Use Committee of Children’s Hospital, Boston.
Statistics
Data were expressed as average ± standard error of the mean (SEM) of at least
three independent experiments. An unpaired, two-tailed Student’s t test was
used to determine differences between two groups. For the tumor incidence
study, statistical analyses were performed using the log-rank (Mantel-Cox).SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and one table and can be found with this article online at http://dx.doi.
org/10.1016/j.cell.2013.04.023.
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